{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-25-048814","form_type":"8-K","ticker":"CORT","cik":"0001088856","company_name":"CORCEPT THERAPEUTICS INC","filed_at":"2025-11-04T23:59:59+00:00","discovered_at":"2026-05-14T18:02:38.765516+00:00","generated_at":"2026-05-17T00:32:16.240949+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Corcept Q3 revenue rises to $207.6M but net income drops; 2025 guidance modified to $800-850M","bullets":["Revenue $207.6M (+14% YoY); net income $19.7M ($0.16 diluted EPS) vs $47.2M ($0.41) in Q3 2024.","Modified 2025 revenue guidance to $800-850M, citing capacity constraints at prior specialty pharmacy.","Cash and investments $524.2M; repurchased $50.6M in stock during Q3.","NDA for relacorilant in hypercortisolism PDUFA Dec 30, 2025; NDA for ovarian cancer PDUFA July 11, 2026.","New oncology trials starting: Phase 2 in earlier-stage ovarian, endometrial, cervical, pancreatic cancers; Phase 1b for nenocorilant with immunotherapy."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-25-048814","json":"https://secwatch.observer/filing/0001628280-25-048814.json","markdown":"https://secwatch.observer/filing/0001628280-25-048814.md","text":"https://secwatch.observer/filing/0001628280-25-048814.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1088856/000162828025048814/0001628280-25-048814-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1088856/000162828025048814/cort-20251104.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T00:32:16.240949+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}